Boston Scientific enrolled the first patient in its renal denervation trial as the quest to prove the procedure's efficacy at lowering hypertension continues in the wake of the Medtronic's disastrous SYMPLICITY trial results, from which the field is still recovering.
As evidence of the danger posed by cancer-spreading power morcellation mounted, there was intense debate within the medical device and healthcare communities. The solutions proposed were narrow in nature, such as the use of surgical bags during morcellation. But America's Health Insurance Plans says the safety scare points to the need for broader regulatory reform in a letter to Sen. Robert Casey (D-PA) noting that "the serious gaps in the current approval and post monitoring process for medical devices."
PatientsLikeMe and Biogen revealed promising results from a new study that shows wearable devices can help monitor individuals with MS over time, providing additional information to clinicians and potentially increasing adherence among patients.
California's InPress Technologies completed the first human trial of its innovative device for postpartum hemorrhages, or excessive bleeding after childbirth, a milestone for the company as it eyes U.S. regulatory approval for the product.
POPULAR COMMENT THREADS
The venture capital invested in med tech startups dipped below $500 million during the first quarter--for the first time since the fourth quarter of 2013, according to the MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association based on data provided by Thomson Reuters.
Novartis' Alcon received FDA approval for its implantable AcrySof IQ ReSTOR +2.5 Diopter intraocular lens, enabling vision correction at all distances in eye care patients with or without presbyopia who undergo cataract surgery.
The U.K. is well known for examining healthcare costs closely and incorporating them into decision-making on spending. Now, in order to help cut healthcare costs and address a nursing shortage that is squeezing countries internationally, the government agency Innovate UK is funding a trial for a camera-based vital sign technology from startup Oxehealth.
Thoratec touted clinical trial data presented at an International Society for Heart and Lung Transplantation meeting in Nice, France, showing that advanced heart failure patients who receive ambulatory--or outpatient--care are better off using its HeartMate II left ventricular assist device than receiving optimal medical management.
Cartiva has raised $6 million to back its musculoskeletal foot surgical products from a single investor just ahead of its first PMA review. The financing could be expanded to up to $8.5 million, according to an SEC filing. The startup has previously identified New Enterprise Associates, which has a partner on its board, as its primary investor.
EndoGastric Solutions is trumpeting promising study data for its device for gastroesophageal reflux disease, weeks after the company picked up a reimbursement code for its procedure to treat the condition.
From Our Sister Sites
Sanofi has reached out to its French neighbor Innate Pharma to collaborate on armed antibody treatments, borrowing the biotech's technology to craft new treatments for cancer and inflammatory disease.
The immuno-oncology drug Opdivo from Bristol-Myers Squibb continued on its charmed path today when the drugmaker cut short another trial for lung cancer because it had nailed its goal for overall survival. This comes after accelerated FDA approval of Opdivo for melanoma and then lung cancer, which has led analysts to keep jacking up earnings forecast, now to $7 billion in annual sales in 5 years.